A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs IPI 549 (Primary) ; Nivolumab
  • Indications Adrenocortical carcinoma; Breast cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2018 According to an Infinity Pharmaceuticals media release, company expects to begin enrollment in combination expansion cohort of patients with high baseline levels of MDSCs in the first quarter of 2018.
    • 08 Jan 2018 According to an Infinity Pharmaceuticals media release, The monotherapy dose-escalation component is complete and the monotherapy expansion component has been fully enrolled. The combination dose-escalation component is also complete, and six disease-specific combination expansion cohorts are open to enrollment. Seventh combination expansion cohort of IPI-549 with Opdivo to include cancer patients with high baseline levels of myeloid derived suppressor cells is added in the study.
    • 08 Jan 2018 According to an Infinity Pharmaceuticals media release, data from the monotherapy expansion component, data from the combination dose-escalation component and initial data from the combination expansion component of the study are expected in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top